Fig 1.
PRISMA diagram of the process for selection of relevant studies.
Table 1.
General characteristics of the included studies for meta-analysis.
Fig 2.
Forest plot of efficacy evaluation results.
Changes in LDL-C observed for high-intensity statin monotherapy and low/moderate-intensity statin plus ezetimibe combination therapy. a rosuvastatin 20 mg vs. rosuvastatin 5 mg plus ezetimibe 10 mg; b rosuvastatin 20 mg vs. rosuvastatin 10 mg plus ezetimibe 10 mg; c rosuvastatin 20 mg vs. atorvastatin 10 mg plus ezetimibe 10 mg; d atorvastatin 40 mg vs. atorvastatin 10 mg plus ezetimibe 10 mg.
Fig 3.
Forest plot of efficacy evaluation results.
Changes in TC observed for high-intensity statin monotherapy and low/moderate-intensity statin plus ezetimibe combination therapy. a rosuvastatin 20 mg vs. rosuvastatin 5 mg plus ezetimibe 10 mg; b rosuvastatin 20 mg vs. rosuvastatin 10 mg plus ezetimibe 10 mg; c rosuvastatin 20 mg vs. atorvastatin 10 mg plus ezetimibe 10 mg; d atorvastatin 40 mg vs. atorvastatin 10 mg plus ezetimibe 10 mg.
Fig 4.
Forest plot of efficacy evaluation results.
Changes in Triglyceride observed for high-intensity statin monotherapy and low/moderate-intensity statin plus ezetimibe combination therapy. a rosuvastatin 20 mg vs. rosuvastatin 5 mg plus ezetimibe 10 mg; b rosuvastatin 20 mg vs. rosuvastatin 10 mg plus ezetimibe 10 mg; c rosuvastatin 20 mg vs. atorvastatin 10 mg plus ezetimibe 10 mg; d atorvastatin 40 mg vs. atorvastatin 10 mg plus ezetimibe 10 mg.
Fig 5.
Forest plot of efficacy evaluation results.
Changes in HDL-C observed for high-intensity statin monotherapy and low/moderate-intensity statin plus ezetimibe combination therapy. a rosuvastatin 20 mg vs. rosuvastatin 5 mg plus ezetimibe 10 mg; b rosuvastatin 20 mg vs. rosuvastatin 10 mg plus ezetimibe 10 mg.
Fig 6.
Forest plot of efficacy evaluation results.
Changes in hs-CRP observed for high-intensity statin monotherapy and low/moderate-intensity statin plus ezetimibe combination therapy.
Fig 7.
Forest plot of safety evaluation results.
Changes in ALT observed for high-intensity statin monotherapy and low/moderate-intensity statin plus ezetimibe combination therapy.
Fig 8.
Forest plot of safety evaluation results.
Changes in AST observed for high-intensity statin monotherapy and low/moderate-intensity statin plus ezetimibe combination therapy.
Fig 9.
Forest plot of safety evaluation results.
Changes in CK observed for high-intensity statin monotherapy and low/moderate-intensity statin plus ezetimibe combination therapy.
Table 2.
Test of heterogeneity and publication bias.